Adults as young as 50 may now qualify for an RSV vaccine if they have certain health conditions, according to a quiet update ...

The Food and Drug Administration has approved three vaccines for RSV — GSK's GSK.L Arexvy, Moderna's MRNA.O mRESVIA and Pfizer's PFE.N Abrysvo.

The U.S. CDC recommends RSV vaccines for high-risk adults aged 50-59, endorsing the views of the former vaccine advisory ...

Adults as young as 50 may now qualify for an RSV vaccine if they have certain health conditions, according to a recent CDC update.

The Trump administration appears to be expanding RSV vaccinations to some adults starting at age 50 instead of 60.

The chair of the CDC’s newly remade vaccine advisory committee said Wednesday that the committee will be reviewing existing vaccine recommendations and assessing whether people receive too ...

The new RSV recommendation calls for a single dose of vaccine for adults age 50 to 59 years who are at increased risk of severe RSV disease.

The U.S. Centers for Disease Control and Prevention has accepted recommendations made by an advisory panel in April on the use of respiratory syncytial virus vaccines in adults aged between 50 and ...

The U.S. Centers for Disease Control and Prevention has accepted recommendations made by a panel of vaccine experts in April, months before they were abruptly fired by U.S. Health Secretary Robert F ...

Shares of Moderna MRNA rose nearly 6% yesterday after the U.S. Centers for Disease Control and Prevention (“CDC”) adopted new recommendations for the use of RSV vaccines in the upcoming respiratory ...

The U.S. Centers for Disease Control and Prevention has accepted recommendations made by an advisory panel in April on the use of respiratory syncytial virus vaccines in adults aged between 50 and 59 ...

Moderna rises as CDC expands RSV vaccine guidance to include high-risk adults aged 50-59, boosting mResvia's reach.